New combo therapy targets Hard-to-Treat prostate cancer
NCT ID NCT05613894
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times
Summary
This study tests a combination of two drugs—cabozantinib (a targeted therapy) and 177Lu-PSMA-617 (a radioactive drug)—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose and see if the combination can slow cancer growth. About 33 participants will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute at University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can targeted radiation tame advanced prostate cancer? a registry aims to find out